Hidradenitis Suppurativa is Associated with Non-alcoholic Fatty Liver Disease: A Cross-sectional Study.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
18 Aug 2020
Historique:
pubmed: 30 7 2020
medline: 29 5 2021
entrez: 30 7 2020
Statut: epublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of end-stage liver disease. The aim of this controlled cross-sectional study was to assess the association between NAFLD and hidradenitis suppurativa. NAFLD was assessed using hepatic ultrasound. A total of 125 patients with hidradenitis suppurativa and 120 patients without hidradenitis suppurativa were recruited, matched for age, sex and body mass index (< 25 or ≥ 25 kg/m2), a risk factor related to NAFLD. Both groups presented similar proportions of overweight or obesity (89.6% vs 90%). Patients with hidradenitis suppurativa presented significantly higher prevalence of NAFLD compared with those with non- hidradenitis suppurativa (57.6% vs 31.7%, p < 0.001). Multivariable analysis confirmed independent association between hidradenitis suppurativa and NAFLD (odds ratio 2.79, 95% confidence interval 1.48-5.25; p = 0.001) besides age, body mass index, hypertension and hypertransaminasaemia. Hidradenitis suppurativa is significantly associated with the development of NALFD regardless of the presence of classic metabolic risk factors.

Identifiants

pubmed: 32725250
doi: 10.2340/00015555-3597
pmc: PMC9207634
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv00239

Références

Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
N Engl J Med. 2012 Jan 12;366(2):158-64
pubmed: 22236226
Drug Metab Rev. 2017 May;49(2):197-211
pubmed: 28303724
J Med Life. 2017 Jan-Mar;10(1):19-26
pubmed: 28255371
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2131-2136
pubmed: 31260574
J Eur Acad Dermatol Venereol. 2018 May;32(5):820-824
pubmed: 29485215
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
J Am Acad Dermatol. 2008 Oct;59(4):596-601
pubmed: 18674845
Dermatol Ther (Heidelb). 2018 Dec;8(4):557-569
pubmed: 30306395
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):656-62
pubmed: 25418531
Therap Adv Gastroenterol. 2012 May;5(3):199-207
pubmed: 22570680
Am J Gastroenterol. 2017 Apr;112(4):581-587
pubmed: 28195177
J Am Acad Dermatol. 2014 Dec;71(6):1144-50
pubmed: 25440440
Gastroenterology. 2005 Jul;129(1):113-21
pubmed: 16012941
Dermatology. 2015;231(2):184-90
pubmed: 26139027
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S27-35
pubmed: 26470611
J Hepatol. 2009 Oct;51(4):778-86
pubmed: 19664838
Gastroenterology. 2011 Jan;140(1):124-31
pubmed: 20858492
Eur J Gastroenterol Hepatol. 2015 Dec;27(12):1392-8
pubmed: 26426833
JAMA Dermatol. 2019 Jul 1;155(7):797-802
pubmed: 30994865
World J Hepatol. 2019 Apr 27;11(4):391-401
pubmed: 31114643
Br J Dermatol. 2017 Nov;177(5):1401-1409
pubmed: 28636793
Addiction. 2016 Jul;111(7):1293-8
pubmed: 27073140
Aliment Pharmacol Ther. 2017 Nov;46(10):974-980
pubmed: 28914448
Aliment Pharmacol Ther. 2007 Apr 15;25(8):883-9
pubmed: 17402991
Br J Dermatol. 2015 Nov;173(5):1142-55
pubmed: 26153913
Australas J Dermatol. 2019 Nov;60(4):e352-e355
pubmed: 30906989
World J Gastroenterol. 2014 Jun 21;20(23):7392-402
pubmed: 24966609
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):129-144
pubmed: 28796920
Diabetes. 2017 Aug;66(8):2241-2253
pubmed: 28490610
J Am Acad Dermatol. 2018 Nov 28;:
pubmed: 30502412
Br J Radiol. 2016 Jun;89(1062):20151024
pubmed: 26876880
World J Gastroenterol. 2013 Oct 28;19(40):6735-43
pubmed: 24187449
Hepatology. 2006 Oct;44(4):865-73
pubmed: 17006923
J Hepatol. 2009 Oct;51(4):758-64
pubmed: 19560226
J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98
pubmed: 19682181
Gastroenterology. 2002 Sep;123(3):745-50
pubmed: 12198701
World J Gastroenterol. 2014 Jun 14;20(22):6821-5
pubmed: 24944472
J Clin Aesthet Dermatol. 2018 Jun;11(6):33-37
pubmed: 29942422
Br J Dermatol. 2003 Jul;149(1):211-3
pubmed: 12890229
Medicine (Baltimore). 2012 Nov;91(6):319-327
pubmed: 23117851

Auteurs

Iris González-Villanueva (I)

Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research, ES-03010 Alicante, Spain. E-mail: jolairis@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH